STERIS reports fiscal 2026 Q4 and full year results
Revenue increased 9% and adjusted EPS rose to $10.17, with a new $1 billion share repurchase program.
See the latest news and media coverage for STERIS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Infection prevention products and services provider
steris.comLast updated
In short: STERIS reported strong fiscal 2026 growth with record Q4 results, announced a $60 million plant expansion, and transitioned to a new CFO.
Revenue increased 9% and adjusted EPS rose to $10.17, with a new $1 billion share repurchase program.
Effective May 5, 2026, Boulud, CEO of bioMérieux, joins with extensive leadership experience in diagnostics and biotech.
Total revenue increases 9% to $1.5 billion. Adjusted EPS rises to $2.53. Fiscal 2026 outlook maintained.
The award honors exceptional revenue growth, financial stability, and stock performance over five years. It ranks publicly traded companies as America's Growth Leaders of 2026.
STERIS (STE) is back in focus after reporting fourth quarter fiscal 2026 results, with adjusted earnings per share of US$2.83 missing consensus by 0.9% and...
Steris faces the risk that substantial cash devoted to new technologies, infrastructure, and manufacturing expansions may not generate the anticipated returns. If these investments underperform...
STERIS plc, a leading provider of medical and cleanroom solutions, has reported strong fourth-quarter (Q4) 2026 results, ...
Asset Allocation- Join our investment platform for free and unlock exclusive stock opportunities, expert research, momentum analysis, and professional trading education trusted by active traders...
Track STERIS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to STERIS and other trending companies.